The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
about
Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in CancerMiR-130a-3p regulates cell migration and invasion via inhibition of Smad4 in gemcitabine resistant hepatoma cells.EMMPRIN Down-regulating miR-106a/b Modifies Breast Cancer Stem-like Cell Properties via Interaction with Fibroblasts Through STAT3 and HIF-1α.Twist1-related miR-26b-5p suppresses epithelial-mesenchymal transition, migration and invasion by targeting SMAD1 in hepatocellular carcinoma.Knockdown of CMTM3 promotes metastasis of gastric cancer via the STAT3/Twist1/EMT signaling pathway.Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2.Rottlerin exerts its anti-tumor activity through inhibition of Skp2 in breast cancer cells.Diagnostic and prognostic value of miR-106a in colorectal cancer.Multiple biological functions of Twist1 in various cancers.Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.The interplay between microRNAs and Twist1 transcription factor: a systematic review.miR-106a suppresses tumor cells death in colorectal cancer through targeting ATG7.Recent progress on the effects of microRNAs and natural products on tumor epithelial-mesenchymal transition.Hippo pathway contributes to cisplatin resistant-induced EMT in nasopharyngeal carcinoma cells.Non-coding RNA in drug resistance of hepatocellular carcinomaExpression of miR-106 in endometrial carcinoma RL95-2 cells and effect on proliferation and invasion of cancer cellsThe Network of Non-coding RNAs in Cancer Drug Resistance
P2860
Q26741846-DE4724E8-454F-4D5E-9EE1-85F77EBCAACEQ36508613-ABCBC900-03E0-4217-B299-61EF538F1D2AQ37023781-CE954B85-256C-4711-8660-3C1D798A0D7AQ37269315-078AB2BE-8559-499D-A7B3-CA4A0C41AD6AQ37301868-19EAA1A5-A395-4C45-B466-B3A3592F2215Q37437206-218F61FB-D85C-4AFF-83F7-C02B0FBC17A1Q37687014-AB3F9E37-4ADE-46EE-B2A5-755D158A61D6Q37706295-182502FC-93FA-401B-BF44-08CF49E68C77Q37746336-1AD31E77-46EC-48F2-9107-ACF68FAAA625Q38546133-B2704EE9-3D31-4A96-9054-BC9B7581CBB1Q38735082-4209480B-9FEC-4EB2-B26B-5C7661BC866CQ39096209-862A8138-E2BA-43DD-9FD4-46BDA5767E40Q39458257-57D84FC3-4FA6-42B8-B851-5F55142DEA5EQ52760977-2EB6285F-3CB0-43F4-B71A-4314EA4A0200Q57156048-2A6A3583-5B05-4FD3-8C23-3AD396530823Q57173328-2A7B0040-BEFE-4541-BF82-1C1BA4D1FC00Q58694197-2A1B180B-1C74-4858-9419-813C626ABAA9
P2860
The PDGF-D/miR-106a/Twist1 pathway orchestrates epithelial-mesenchymal transition in gemcitabine resistance hepatoma cells.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@ast
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@en
type
label
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@ast
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@en
prefLabel
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@ast
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@en
P2093
P2860
P356
P1433
P1476
The PDGF-D/miR-106a/Twist1 pat ...... ine resistance hepatoma cells.
@en
P2093
Changjie Chen
Qingling Yang
Sulian Chen
Yueyue Hou
Zhiwei Wang
P2860
P304
P356
10.18632/ONCOTARGET.3193
P407
P577
2015-03-01T00:00:00Z